NEOANTIGEN
Neoantigen is a high-tech and innovative enterprise specializing in the research and development of individualized tumor vaccines. It is committed to developing various individualized immunotherapy products based on neoantigens. The founder of the company proposed the concept of neoantigen-based therapy in China in 2005 and is one of the leaders in the research and development of neoantigen-related products in the world.
NEOANTIGEN
Industry:
Information Services Information Technology Market Research
Founded:
2016-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.neoantigen.cn
Status:
Active
Official Site Inspections
http://www.neoantigen.cn
- Host name: 47.98.228.58
- IP address: 47.98.228.58
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Neoantigen"
neoantigen - 纽安津-新生抗原-个体化免疫治疗
杭州纽安津生物科技有限公司成立于2016年，是一家专门从事个体化肿瘤治疗性疫苗研发的高新创新型企业， 致力于开发基于新生抗原的各类个体化 …See details»
Neoantigen 2025 Company Profile: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Neoantigen. Use the PitchBook Platform to explore the full profile.See details»
Neoantigen - Crunchbase Company Profile & Funding
Neoantigen is a high-tech and innovative enterprise specializing in the research and development of individualized tumor vaccines.See details»
Neoantigen - 2025 Company Profile & Team - Tracxn
Neoantigen is a seed company based in Hangzhou (China), founded in 2016 by Fan Mo and Chen Shuqing. It operates as a Developer of immuno therapeutics for treating cancer. …See details»
纽安津生物 | 项目信息-36氪
纽安津生物成立于2016年，是一家专注于研发基于肿瘤新生抗原的个体化免疫治疗技术的高新企业，致力于通过领先的人工智能分析技术筛选肿瘤细胞 …See details»
Pharmaceutical tech company founds headquarters in Luohu
Updated: 2023-06-08 From: China.org.cn Pharmaceutical tech company founds headquarters in Luohu Neoantigen, a pharmaceutical technology company, recently founded its headquarters …See details»
Neoantigens: promising targets for cancer therapy
Jan 6, 2023 Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, …See details»
关于我们-纽安津-新生抗原-个体化免疫治疗
杭州纽安津生物科技有限公司成立于2016年，是一家专门从事个体化肿瘤治疗性疫苗研发的高新创新型企业， 致力于开发基于新生抗原的各类个体化 …See details»
Neodb - Database Commons
Aug 23, 2023 Neodb: a comprehensive neoantigen database and discovery platform for cancer immunotherapy. [PMID: 37311149]See details»
Neoantigen: A New Breakthrough in Tumor Immunotherapy
With the wide application of fl multi-omics high-throughput technologies and the development of neoantigen prediction technology, neoantigen-based immunotherapy becomes a new research …See details»
新闻-纽安津-新生抗原-个体化免疫治疗 - neoantigen
纽安津生物完成数千万元A轮融资，加速新生抗原产品管线推进 近日，杭州纽安津生物科技有限公司（简称：纽安津生物）完成数千万元的A轮融资， …See details»
新闻中心-纽安津-新生抗原-个体化免疫治疗 - neoantigen
Dec 21, 2023 《Nature Medicine》|个体化新生抗原特异性T细胞疗法对免疫检查点抑制剂无效的转移性黑色素瘤患者安全有效 纽安津 2025-07-16See details»
Neoantigen vaccine: an emerging tumor immunotherapy
Aug 23, 2019 Further development of sequencing technologies and bioinformatics algorithms, as well as an improvement in our understanding of the mechanisms underlying tumor …See details»
Sensitive neoantigen discovery by real-time mutanome-guided ...
6 days ago Most discovery approaches supporting neoantigen-based therapeutics rely solely on computational pipelines to predict immunogenic neoantigens from next-generation sequencing …See details»
产品-纽安津-新生抗原-个体化免疫治疗 - neoantigen
新生抗原疫苗的可行性评估 该检测能够整体评估患者是否适合新生抗原疫苗治疗，如新生抗原序列分析、新生抗原免疫原性预测，进而评估患者免疫系统被激活的可能性。 同时检测新生抗原 …See details»
Neoantigens: new hope for cancer therapy - Frontiers
Neoantigen immunogenicity, is pivotal for advancing the application and development of tumour neoantigen therapy. The advent of neoantigen-tailored immunotherapy promises to herald a …See details»
NeoAtlas and NeoBert: A Database and A Predictive Model for
Mar 17, 2025 Neoantigens are classified into canonical and noncanonical types. Noncanonical neoantigens include those derived from noncoding regions, transposable elements (TE), and …See details»
Personalized neoantigen cancer vaccines: current progression ...
Sep 26, 2024 The clinical development of personalized neoantigen cancer vaccines is still in the early stage. A clear shift in delivery systems from peptides to DC and liposomal platforms, with …See details»
TumorAgDB
The neoantigen information in the database is freely available for download, supporting further research and clinical applications. So,we are committed to advancing neoantigen research …See details»
Neoantigens: new hope for cancer therapy - Frontiers
Mar 11, 2025 Consequently, the development of neoantigen prediction methodologies with high sensitivity and specificity, capable of swiftly, cost-effectively and efficiently identifying …See details»